[1]孙莹莹,龚先琼.中药单体治疗肝细胞癌的研究[J].医学信息,2021,34(09):33-36.[doi:10.3969/j.issn.1006-1959.2021.09.008]
 SUN Ying-ying,GONG Xian-qiong.Study on the Treatment of Hepatocellular Carcinoma with Chinese Medicine Monomer[J].Medical Information,2021,34(09):33-36.[doi:10.3969/j.issn.1006-1959.2021.09.008]
点击复制

中药单体治疗肝细胞癌的研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年09期
页码:
33-36
栏目:
综述
出版日期:
2021-05-01

文章信息/Info

Title:
Study on the Treatment of Hepatocellular Carcinoma with Chinese Medicine Monomer
文章编号:
1006-1959(2021)09-0033-04
作者:
孙莹莹龚先琼
(1.福建中医药大学第二临床医学院,福建 福州 351012; 2.福建中医药大学附属厦门中医院肝病中心,福建 厦门 361009)
Author(s):
SUN Ying-yingGONG Xian-qiong
(1.The Second Clinical College of Fujian University of Traditional Chinese Medicine,Fuzhou 351012,Fujian,China; 2.Liver Disease Center,Xiamen Traditional Chinese Medicine Hospital,Fujian University of Traditional Chinese Medicine, Xiamen 361009,Fujian,China)
关键词:
肝细胞癌中药单体黄酮类苷类化合物生物碱类化合物
Keywords:
Hepatocellular carcinomaTraditional Chinese medicine monomersFlavonoidsGlycosides Alkaloids
分类号:
R735.7;R730.5
DOI:
10.3969/j.issn.1006-1959.2021.09.008
文献标志码:
A
摘要:
肝细胞癌是最具侵袭性的肿瘤之一,是我国最常见的恶性肿瘤及肿瘤致死病因之一,严重威胁患者的健康和生命。近年来的研究表明中药单体可通过多通路抗肝癌细胞增殖、转移及抗肝癌组织血管生成,本文就黄酮类化合物、苷类化合物、生物碱类化合物及其他化合物等中药单体治疗肝细胞癌的相关研究进展作一综述。
Abstract:
Hepatocellular carcinoma is one of the most aggressive tumors and one of the most common malignant tumors and tumor death causes in China, which seriously threatens the health and lives of patients.Recent studies have shown that Chinese medicine monomers can resist the proliferation and metastasis of liver cancer cells and the angiogenesis of liver cancer tissues through multiple pathways.This article summarizes the research progress of flavonoids, glycosides, alkaloids and other compounds in the treatment of hepatocellular carcinoma.

参考文献/References:

[1]张宏,张浩,刘丽,等.《2018年美国肝病学会肝细胞癌治疗指南》摘译[J].临床肝胆病杂志,2018,34(4):743-748. [2]《原发性肝癌诊疗规范(年版)》编写专家委员会.原发性肝癌诊疗规范(2019年版)[J].中国临床医学,2020,27(1):140-156. [3]钟赣生.中药学供中医学、针灸推拿学、中西医临床医学、中药学等专业用[M].第十版.北京:中国中医药出版社,2016. [4]Huang Y,Liu C,Zeng WC,et al.Isoliquiritigenin inhibits the proliferation, migration and metastasis of Hep3B cells via suppressing cyclin D1 and PI3K/AKT pathway[J].Bioscience Reports,2020,40(1):BSR20192727. [5]Qie S,Diehl JA.Cyclin D1,cancer progression,and opportunities in cancer treatment[J].Journal of Molecular Medicine,2016,94(12):1-14. [6]Leu YL,Wang TH,Wu CC,et al.Hydroxygenkwanin Suppresses Non-Small Cell Lung Cancer Progression by Enhancing EGFR Degradation[J].Molecules,2020,25(4):941. [7]Huang YC,Lee PC,Wang JJ,et al.Anticancer Effect and Mechanism of Hydroxygenkwanin in Oral Squamous Cell Carcinoma[J].Frontiers in Oncology,2019(9):911. [8]Chou LF,Chen CY,Yang WH,et al.Suppression of Hepatocellular Carcinoma Progression through FOXM1 and EMT Inhibition via Hydroxygenkwanin-Induced miR-320a Expression[J].Biomolecules,2019,10(1):20. [9]Bella L,Zona S,Gabriela N,et al.FOXM1:A key oncofoetal transcription factor in health and disease[J].Seminars in Cancer Biology,2014(29):32-39. [10]Zona S,Bella L,Burton M J,et al.FOXM1:An emerging master regulator of DNA damage response and genotoxic agent resistance[J].Biochimica et Biophysica Acta(BBA)- Gene Regulatory Mechanisms,2014,1839(11):1316-1322. [11]Gartel AL.FOXM1 in Cancer:Interactions and Vulnerabilities[J].Cancer Research,2017,77(12):3135-3139. [12]Ke M,Zhang Z,Xu B,et al.Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells[J].International Immunopharmacology,2019(75):105824. [13]Zhang J,Dang F,Ren J,et al.Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy[J].Trends in Biochemical Sciences,2018,43(12):1014-1032. [14]Chen G,Huang AC,Wei Z,et al.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J].Nature,2018,560(7718):382-386. [15]Mandai M,Hamanishi J,Abiko K,et al.Dual Faces of IFN in Cancer Progression:A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity[J].Clinical Cancer Research,2016,22(10):2329-2334. [16]Garcia-Diaz A,Shin DS,Moreno BH,et al.Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression[J].Cell Reports,2017,19(6):1189. [17]Jiang X,Zhou J,Giobbie-Hurder A,et al.The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition[J].Clinical Cancer Research,2013,19(3):598-609. [18]Qin Y,Liu H J,Li M,et al.Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1α signaling pathway[J].E Bio Medicine,2018(38):25-36. [19]Fischer KR,Durrans A,Lee S,et al.Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance[J].Nature,2015,527(7579):472-476. [20]Joseph JP,Mk H,Pillai AA,et al.Hypoxia induced EMT:A review on the mechanism of tumor progression and metastasis in OSCC[J].Oral Oncology,2018(80):23-32. [21]Sun DP,Li XX,Liu XL,et al.Gypenosides Induce Apoptosis by Ca2+ Overload Mediated by Endoplasmic-Reticulum and Store-Operated Ca2+ Channels in Human Hepatoma Cells[J].Cancer Biotherapy&Radiopharmaceuticals,2013,28(4):320-326. [22]Wang QF,Chen JC,Hsieh SJ,et al.Regulation of Bcl-2 family molecules and activation of caspase cascade involved in gypenosides-induced apoptosis in human hepatoma cells[J].Cancer Letters,2002,183(2):169-178. [23]Zheng K,Liao C,Li Y,et al.Gypenoside L,Isolated from Gynostemma pentaphyllum,Induces Cytoplasmic Vacuolation Death in Hepatocellular Carcinoma Cells through Reactive-Oxygen-Species-Mediated Unfolded Protein Response[J].Journal of Agricultural&Food Chemistry,2016,64(8):1702. [24]Chen K,Zhu P,Ye J,et al.Oxymatrine inhibits the migration and invasion of hepatocellular carcinoma cells by reducing the activity of MMP-2/-9 via regulating p38 signaling pathway[J].Journal of Cancer,2019,10(22):5397-5403. [25]Song J,Zhang X,Ge Q,et al.CRISPR/Cas9﹎ediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells[J].Journal of Cellular Biochemistry,2018,119(10):8419-8431. [26]Chen J,Xiao X,Qi L,et al.Role of Pittsburgh Modified TNM Criteria in prognosis prediction of liver transplantation for hepatocellular carcinoma[J].Chinese Medical Journal,2007,120(24):2200-2203. [27]Gialeli C,Theocharis AD,Karamanos NK.Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting[J].FEBS Journal,2011,278(1):16-27. [28]Zhang Q,Chen W,Lv X,et al.Piperlongumine,a Novel TrxR1 Inhibitor,Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress[J].Frontiers in Pharmacology,2019(10):1180. [29]Kapoor S.Tumor growth attenuating effect of celastrol in systemic malignancies[J].Journal International Du Cancer,2016,139(6):1431. [30]Vliet A,Garg A D,Agostinis P.Coordination of stress,Ca2+,and immunogenic signaling pathways by PERK at the endoplasmic reticulum[J].Biological Chemistry,2016,397(7):649-656. [31]Schleicher SM,Moretti L,Varki V,et al.Progress in the unraveling of the endoplasmic reticulum stress/autophagy pathway and cancer:implications for future therapeutic approaches[J].Drug Resist Updat,2010,13(3):79-86. [32]Bo R,Hui L,Hang G,et al.Celastrol induces apoptosis in hepatocellular carcinoma cells via targeting ER-stress/UPR[J].Oncotarget,2017,8(54):93039-93050. [33]Shao S,Duan W,Xu Q,et al.Curcumin Suppresses Hepatic Stellate Cell-Induced Hepatocarcinoma Angiogenesis and Invasion through Downregulating CTGF[J].Oxidative Medicine&Cellular Longevity,2019(2019):8148510. [34]Lucas J,Hsieh TC,Halicka HD,et al.Upregulation of PD?L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300mediated NFκB signaling[J].International Journal of Oncology,2018,53(4):1469-1480. [35]Zhang B,Yin X,Sui S.Resveratrol inhibited the progression of human hepatocellular carcinoma by inducing autophagy via regulating p53 and the phosphoinositide3kinase/protein kinaseB pathway[J].Oncology Reports,2018,40(5):2758-2765. [36]Huang WH,Liao WR,Sun RX.Astragalus polysaccharide induces the apoptosis of human hepatocellular carcinoma cells by decreasing the expression of Notch1[J].International Journal of Molecular Medicine,2016,38(2):551-557. [37]Yoshida R,Nagata M,Nakayama H,et al.The pathological significance of Notch1 in oral squamous cell carcinoma[J].Laboratory Investigation,2013,93(10):1068-1081. [38]Wang F,Hou W,Chitsike L,et al.ABL1,Overexpressed in Hepatocellular Carcinomas,Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice[J].Gastroenterology,2020,159(1):289-305,e16. [39]Zhu MS,Xu LB,Hong Z,et al.Association of Notch1 with vasculogenic mimicry in human hepatocellular carcinoma cell lines[J].International Journal of Clinical And Experimental Pathology,2014,7(9):5782-5791.

相似文献/References:

[1]王利娜,赵雪梅,徐云霞,等.磁共振扩散张量成像在肝细胞癌及 肝转移瘤鉴别诊断价值研究[J].医学信息,2018,31(09):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
 WANG Li-na,ZHAO Xue-mei,XU Yun-xia,et al.Diagnostic Value of Magnetic Resonance Diffusion Tensor Imaging in Hepatocellular Carcinoma and Liver Metastases[J].Medical Information,2018,31(09):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
[2]李珊珊,陈少彬,龚先琼.中药单体治疗非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(21):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
 LI Shan-shan,CHEN Shao-bin,GONG Xian-qiong.Advances in Research of Traditional Chinese Medicine Monomer in the Treatment of Non-alcoholic Fatty Liver Disease[J].Medical Information,2018,31(09):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
[3]林思萍,龚先琼.中药单体调控TGF-β1/Smads信号通路抗纤维化的研究[J].医学信息,2019,32(21):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
 LIN Si-ping,GONG Xian-qiong.Study on Anti-Fibrosis of TGF-β1/Smads Signaling Pathway Regulated by Chinese Medicine Monomer[J].Medical Information,2019,32(09):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
[4]刘 冰,杨 帅,费锡斌,等.GPC-3联合CK-19免疫组化检测在肝细胞癌诊断及鉴别诊断中的应用[J].医学信息,2019,32(23):169.[doi:10.3969/j.issn.1006-1959.2019.23.054]
 LIU Bing,YANG Shuai,FEI Xi-bin,et al.Application of GPC-3 Combined with CK-19 Immunohistochemical Detection in Diagnosis and Differential Diagnosis of Hepatocellular Carcinoma[J].Medical Information,2019,32(09):169.[doi:10.3969/j.issn.1006-1959.2019.23.054]
[5]钟小丽,龚先琼.基于JAK2/STAT3信号通路探讨中药单体治疗肝癌的研究[J].医学信息,2020,33(01):21.[doi:10.3969/j.issn.1006-1959.2020.01.009]
 ZHONG Xiao-li,GONG Xian-qiong.Study on the Treatment of Liver Cancer with Traditional Chinese Medicine Monomer Based on JAK2/STAT3 Signaling Pathway[J].Medical Information,2020,33(09):21.[doi:10.3969/j.issn.1006-1959.2020.01.009]
[6]李文华,许传斌,崔景景,等.基于治疗前MR-T2WI影像组学特征预测肝细胞癌射频消融术后早期复发的价值[J].医学信息,2022,35(18):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
 LI Wen-hua,XU Chuan-bin,CUI Jing-jing,et al.The Value of Predicting Early Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Based on Pre-treatment MR-T2WI Radiomics Features[J].Medical Information,2022,35(09):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
[7]彭莉蓉,黎村艳,史 杨.肿瘤微环境免疫细胞中差异lncRNA对肝细胞癌预后的预测价值[J].医学信息,2022,35(20):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
 PENG Li-rong,LI Cun-yan,SHI Yang.The Predictive Value of Differential lncRNA in Tumor Microenvironment Immune Cells for the Prognosis of Hepatocellular Carcinoma[J].Medical Information,2022,35(09):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
[8]刘丽丽.CLCVP对肝细胞癌行腹腔镜肝叶切除手术相关指标及肝门阻断时间的影响[J].医学信息,2020,33(19):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
 LIU Li-li.The Effect of CLCVP on the Operation-related Indexes and Port Occlusion Time in Patients with Hepatocellular Carcinoma Undergoing Laparoscopic Lobectomy[J].Medical Information,2020,33(09):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
[9]林芳芳,龚先琼.中药单体治疗酒精性肝损伤的研究现状[J].医学信息,2021,34(05):32.[doi:10.3969/j.issn.1006-1959.2021.05.010]
 LIN Fang-fang,GONG Xian-qiong.Advances in the Treatment of Alcoholic Liver Injury by Monomer of Traditional Chinese Medicine[J].Medical Information,2021,34(09):32.[doi:10.3969/j.issn.1006-1959.2021.05.010]
[10]裴金仙,陈天狮,任巧晶,等.JAK2/STAT3通路在HBV相关肝细胞癌中表达及机制研究[J].医学信息,2022,35(24):59.[doi:10.3969/j.issn.1006-1959.2022.24.012]
 PEI Jin-xian,CHEN Tian-shi,REN Qiao-jing,et al.The Expression and Mechanism of JAK2/STAT3 Pathway in HBV-related Hepatocellular Carcinoma[J].Medical Information,2022,35(09):59.[doi:10.3969/j.issn.1006-1959.2022.24.012]

更新日期/Last Update: 1900-01-01